Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Azoth Analytics | PRODUCT CODE: 1063537

Cover Image

PUBLISHER: Azoth Analytics | PRODUCT CODE: 1063537

Global Generic Injectables Market (2022 Edition) - Analysis By Molecule Type, (Small, Large), Therapeutic Area, Container Type, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2022-2027)

PUBLISHED:
PAGES: 240 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 2400
PDF (Enterprise License)
USD 3000

Add to Cart

Executive Summary

The global generic injectables market was valued at USD 134 billion in the year 2021 with the North American region leading the regional market share. Some of the key factors driving the generic injectables market growth are the expiration of branded drug patents, rising approvals for generic injectable drugs, rising aged population and the rising prevalence of life-threatening diseases among the global population. In addition, as compared to the costs of branded drugs, generic injectables are relatively inexpensive and used in the treatment of major diseases such as cancer, cardiovascular diseases, diabetes, and so on that further supports market demand.

The Asia Pacific is estimated to be the fastest-growing region due to the growing focus of Indian companies on complex generics and the rise in the adoption of generic injectables due to its cost-efficient nature. In addition, the APAC countries (China and India) have the highest prevalent cases of different chronic diseases, which is projected to fuel the market growth in upcoming years. Meanwhile, North America will remain the dominant region in the global Generic Injectables market. The United States in the North American region and China in Asia-Pacific are the major countries in the Generic Injectables market globally.

The outbreak of COVID-19 showed an impact on the global generic injectables market because hospitals, healthcare services, and drug manufacturers were significantly affected due to a variety of restrictions imposed by governments across the globe such as social distancing, travel restrictions, border closures, restrictions on public gatherings, work from home and so on. COVID-19 has had a direct impact on both supply and demand and created disruption in the supply chain, as many injectable drugs could not reach the market on time. Although the impact of COVID-19 in the pharmaceutical industry was a bit lesser compared to other industries, it still has been harmed in some ways. Many clinical trials were delayed due to the pandemic, as researchers were not permitted to visit the laboratories and continue those ongoing trials. If there were no disruptions, those molecules would come into the market as a patented molecule, hence increasing the generic injectables market in the forecast period.

Pfizer Inc. is the world's leading generic injectables company, having strengthened its position through the introduction of several generic injectable drugs as well as mergers & partnerships with regional pharma companies. Recently in 2021, Pfizer Inc. partnered with Eli Lilly and Company, an American pharmaceutical company, to announce the approval of tanezumab, a generic injectable drug for treating osteoarthritis pain in the United States. With more branded drugs coming off patent in the coming years, Pfizer has a clear plan to develop generic versions of those injectables and obtain FDA approvals to bring them to market.

Scope of the Report

  • The report analyses the Generic Injectables Market by Value (USD Billion).
  • The report presents the analysis of Generic Injectables Market for the historical period of 2017-2021 and the forecast period of 2022-2027.
  • The report analyses the Generic Injectables Market by Molecule Type (Small Molecule, Large Molecule).
  • The report analyses the Generic Injectables Market by Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes, Others)
  • The report analyses the Generic Injectables Market by Container (Vials, Ampoules, Pre-filled Syringes and Others)
  • The Global Generic Injectables Market has been analysed By Region (North America, Europe, Asia Pacific, and LAMEA).
  • The Global Generic Injectables Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India, Australia).
  • The key insights of the report have been presented through the frameworks of SWOT Analysis. Also, the attractiveness of the market has been presented by region, by Molecule Type, by Therapeutic Area and by Container.
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
  • The report tracks competitive developments, strategies, and a List of First-Time Generic Injectables Approvals in 2021. The companies analysed in the report include Pfizer Inc., Novartis, Sanofi, Baxter International, Fresenius SE & Co KGaA, Amneal Pharmaceuticals, Hikma Pharmaceuticals, Gland Pharma, Teva Pharmaceuticals and Nichi-iko Pharmaceutical.

Key Target Audience

  • Injectable Drug Manufacturers & Distributors
  • Pharmaceutical, Biopharmaceutical & Biotechnological Companies
  • End Users (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers & Others)
  • Research and Development (R&D) Organizations
  • Government Bodies & Regulating Authorities
  • Investment Banks and Equity Firms

Table of Contents

1. Report Scope and Methodology

  • 1.1 Scope of the Report
  • 1.2 Research Methodology
  • 1.3 Executive Summary

2. Strategic Recommendations

3. Generic Injectables Market: Product Overview

4. Global Generic Injectables Market: An Analysis

  • 4.1 Market Size, By Value, 2017-2027
  • 4.2 Global Generic Injectables Market: Growth & Forecast
  • 4.3 Impact of COVID-19 on Generic Injectables Market

5. Global Generic Injectables Market Segmentation, By Molecule Type (Value)

  • 5.1 Competitive Scenario of Global Generic Injectables Market: By Molecule Type
  • 5.2 Global Generic Injectables Market: Segment Analysis
  • 5.3 By Small Molecule - Market Size and Forecast (2017-2027)
  • 5.4 By Large Molecule - Market Size and Forecast (2017-2027)

6. Global Generic Injectables Market Segmentation, By Therapeutic Area (Value)

  • 6.1 Competitive Scenario of Global Generic Injectables Market: By Therapeutic Area (2021 & 2027)
  • 6.2 Global Generic Injectables Market: Segment Analysis
  • 6.3 By Oncology - Market Size and Forecast (2017-2027)
  • 6.4 By Anti-infectives - Market Size and Forecast (2017-2027)
  • 6.5 By Cardiovascular - Market Size and Forecast (2017-2027)
  • 6.6 By Diabetes - Market Size and Forecast (2017-2027)
  • 6.7 By Others - Market Size and Forecast (2017-2027)

7. Global Generic Injectables Market Segmentation, By Container (Value)

  • 7.1 Competitive Scenario of Global Generic Injectables Market: By Container (2021 & 2027)
  • 7.2 Global Generic Injectables Market: Segment Analysis
  • 7.3 By Vials - Market Size and Forecast (2017-2027)
  • 7.4 By Ampoules - Market Size and Forecast (2017-2027)
  • 7.5 By Pre-filled Syringes - Market Size and Forecast (2017-2027)
  • 7.6 By Others - Market Size and Forecast (2017-2027)

8. Global Generic Injectables Market: Regional Analysis

  • 8.1 Competitive Scenario of Global Generic Injectables Market: By Region (2021 & 2027)

9. North America Generic Injectables Market: An Analysis (2017-2027)

  • 9.1 North America Generic Injectables Market: Size and Forecast (2017-2027), By Value
  • 9.2 North America Generic Injectables Market - Prominent Companies
  • 9.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)
  • 9.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)
  • 9.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)
  • 9.6 North America Generic Injectables Market: Country Analysis
  • 9.7 Market Opportunity Chart of North America Generic Injectables Market - By Country, By Value (Year-2026)
  • 9.8 Competitive Scenario of North America- By Country
  • 9.9 United States Generic Injectables Market: Size and Forecast (2017-2027), By Value
  • 9.10 United States Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
  • 9.11 Canada Generic Injectables Market: Size and Forecast (2017-2027), By Value
  • 9.12 Canada Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

10. Europe Generic Injectables Market: An Analysis (2017-2027)

  • 10.1 Europe Generic Injectables Market by value: Size and Forecast (2017-2027)
  • 10.2 Europe Generic Injectables Market: Prominent Companies
  • 10.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)
  • 10.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)
  • 10.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)
  • 10.6 Europe Generic Injectables Market: Country Analysis
  • 10.7 Market Opportunity Chart of Europe Generic Injectables Market - By Country, By Value (Year-2026)
  • 10.8 Competitive Scenario of Europe Generic Injectables Marketn By Country (2021 & 2027)
  • 10.9 Germany Generic Injectables Market: Size and Forecast (2017-2027)
  • 10.10 Germany Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
  • 10.11 United Kingdom Generic Injectables Market: Size and Forecast (2017-2027)
  • 10.12 United Kingdom Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
  • 10.13 France Generic Injectables Market: Size and Forecast (2017-2027)
  • 10.14 France Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
  • 10.15 Italy Generic Injectables Market: Size and Forecast (2017-2027)
  • 10.16 Italy Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

11. Asia Pacific Generic Injectables Market: An Analysis (2017-2027)

  • 11.1 Asia Pacific Generic Injectables Market by value: Size and Forecast (2017-2027)
  • 11.2 Asia Pacific Generic Injectables Market: Prominent Companies
  • 11.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)
  • 11.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)
  • 11.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)
  • 11.6 Asia Pacific Generic Injectables Market: Country Analysis
  • 11.7 Market Opportunity Chart of Asia Pacific Generic Injectables Market - By Country, By Value (Year-2026)
  • 11.8 Competitive Scenario of Asia Pacific Generic Injectables Market - By Country (2021 & 2027)
  • 11.9 China Generic Injectables Market: Size and Forecast (2017-2027)
  • 11.10 China Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
  • 11.11 Japan Generic Injectables Market: Size and Forecast (2017-2027)
  • 11.12 Japan Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
  • 11.13 India Generic Injectables Market: Size and Forecast (2017-2027)
  • 11.14 India Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)
  • 11.15 Australia Generic Injectables Market: Size and Forecast (2017-2027)
  • 11.16 Australia Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

12. Global Generic Injectables Market Dynamics

  • 12.1 Global Generic Injectables Market Drivers
  • 12.2 Global Generic Injectables Market Restraints
  • 12.3 Global Generic Injectables Market Trends

13. Market Attractiveness and Strategic Analysis

  • 13.1 Market Attractiveness Chart of Global Generic Injectables Market - By Molecule Type (Year 2027)
  • 13.2 Market Attractiveness Chart of Global Generic Injectables Market - By Therapeutic Area (Year 2027)
  • 13.3 Market Attractiveness Chart of Global Generic Injectables Market n By Container (Year 2027)
  • 13.4 Market Attractiveness Chart of Global Generic Injectables Market n By Region (Year 2027)

14. Competitive Landscape

  • 14.1 Market Share of global leading companies
  • 14.2 Market Share of Leading US Companies by Value & by Volume
  • 14.3 SWOT Analysis - Global Generic Injectables Market

15. Global Generic Injectables Market: List of First-Time Generic Injectables Approvals in 2021

16. Company Profiles (Business Description, Financial Analysis, Business Strategy)

  • 16.1 Pfizer Inc.
  • 16.2 Novartis
  • 16.3 Sanofi
  • 16.4 Baxter International
  • 16.5 Fresenius SE & Co KGaA
  • 16.6 Amneal Pharmaceuticals
  • 16.7 Hikma Pharmaceuticals
  • 16.8 Gland Pharma
  • 16.9 Teva Pharmaceuticals
  • 16.10 Nichi-iko Pharmaceutical

List of Figures

List of Figures

  • Figure 1: Global Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 2: Global Estimated number of Cancer incidences and prevalent cases (all ages, in millions), Year 2020
  • Figure 3: Global Cancer related number of deaths (all ages, in thousand's), Year 2020
  • Figure 4: Global Estimated number of Diabetes prevalent cases (adults (20-79), in millions), Year 2021
  • Figure 5: Global Prevalence of Cardiovascular Diseases, (in million), 2015-2019
  • Figure 6: Global Aged Population (Above 65), 2015-20 (% of total Population)
  • Figure 7: Global Aged Population (Above 65), By Country, 2020 (% of total Population)
  • Figure 8: Global Medical Spending in 2020, By Region, (% of Total)
  • Figure 9: Current Healthcare Expenditure (% Share of GDP), By Selected Country, 2016-2020 (In %)
  • Figure 10: Global Expected Healthcare Industry Outlook
  • Figure 11: Regional Expected Healthcare Industry Growth Rate By Year 2024
  • Figure 12: Global Generic Injectables Market- By Molecule Type Market Share, 2021 & 2027
  • Figure 13: Global Generic Injectables Market- By Small Molecule, By Value (USD Billion), 2017-2027
  • Figure 14: Global Generic Injectables Market- By Large Molecule, By Value (USD Billion), 2017-2027
  • Figure 15: Global Generic Injectables Market - By Therapeutic Area Market Share, 2021 & 2027
  • Figure 16: Global Generic Injectables Market- By Oncology, By Value (USD Billion), 2017-2027
  • Figure 17: Global Generic Injectables Market- By Anti-infectives, By Value (USD Billion), 2017-2027
  • Figure 18: Global Generic Injectables Market- By Cardiovascular, By Value (USD Billion), 2017-2027
  • Figure 19: Global Generic Injectables Market- By Diabetes, By Value (USD Billion), 2017-2027
  • Figure 20: Global Generic Injectables Market- By Others, By Value (USD Billion), 2017-2027
  • Figure 21: Global Generic Injectables Market- By Container Market Share, 2021 & 2027
  • Figure 22: Global Generic Injectables Market- By Vials, By Value (USD Billion), 2017-2027
  • Figure 23: Global Generic Injectables Market- By Ampoules, By Value (USD Billion), 2017-2027
  • Figure 24: Global Generic Injectables Market- By Pre-filled Syringes, By Value (USD Billion), 2017-2027
  • Figure 25: Global Generic Injectables Market- By Others, By Value (USD Billion), 2017-2027
  • Figure 26: Global Generic Injectables Market- By Region Market Share, 2021 & 2027
  • Figure 27: North America Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 28: Prevalence of Cardiovascular Diseases in North America, (in million), 2015-2019
  • Figure 29: Cancer prevalence in North America (in million), Year 2020
  • Figure 30: Prevalence of Multiple Sclerosis in North America, (in 1000is), 2015-2019
  • Figure 31: North America Diabetes Prevalence, By Country, 2020 (% of Population Aged 20-79)
  • Figure 32: North America Diabetes-related health expenditure per person, USD (Year 2021)
  • Figure 33: North America Current health expenditure per capita (current USD), 2014-18
  • Figure 34: North America Population ages 65 and above (% of total Population), 2016-20
  • Figure 35: North America Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 36: North America Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 37: North America Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 38: Market Opportunity Chart of North America Generic Injectables Market- By Country, By Value (Year-2027)
  • Figure 39: North America Generic Injectables Market- By Country Market Share, 2021 & 2027
  • Figure 40: United States Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 41: Prevalence of Cardiovascular Diseases in United States, (in million), 2015-2019
  • Figure 42: Prevalence of Multiple Sclerosis in United States, (in 1000is), 2016-2019
  • Figure 43: Cancer prevalence in United States (in million), Year 2020
  • Figure 44: United States Current health expenditure per capita (current USD), 2016-2020
  • Figure 45: United States Population aged 65 and above (% of total Population), 2016-20
  • Figure 46: Estimated people with diabetes in United States (in millions), 2021-2045
  • Figure 47: United States Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 48: United States Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 49: United States Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 50: Canada Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 51: Prevalence of Cardiovascular Diseases in Canada, (in million), 2015-2019
  • Figure 52: Estimated number of Cancer Prevalent cases in Canada, 2020
  • Figure 53: Prevalence of Multiple sclerosis in Canada, (in 1000is), 2016-2019
  • Figure 54: Canada Current health expenditure per capita (current USD), 2017-2021
  • Figure 55: Canada Population aged 65 and above (% of total Population), 2016-20
  • Figure 56: Estimated people with diabetes in Canada (in millions), 2021-2045
  • Figure 57: Canada Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 58: Canada Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 59: Canada Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 60: Europe Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 61: Europe Prevalence of Cardiovascular Diseases (in Million), 2015-2019
  • Figure 62: Prevalence of Osteoarthritis Diseases in Europe, (in Million), 2015-2019
  • Figure 63: Europe estimated number of Cancer prevalence (all ages, in Million), Year 2020
  • Figure 64: Europe Prevalence of Multiple Sclerosis, 2016-2019 (In 1000is)
  • Figure 65: Europe Diabetes Prevalence, By Country, 2020 (% of Population Aged 20 to 79)
  • Figure 66: Europe Current health expenditure per capita (current USD), 2015-18
  • Figure 67: Total expenditure on health per capita in European countries (in USD PPP), 2019
  • Figure 68: Population ages 65 and above (% of total Population) in European Countries, 2020
  • Figure 69: Europe Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 70: Europe Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 71: Europe Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 72: Market Opportunity Chart of Europe Generic Injectables Market- By Country, By Value (Year-2026)
  • Figure 73: Europe Generic Injectables Market- By Country Market Share, 2021 & 2027
  • Figure 74: Germany Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 75: Prevalence of Cardiovascular Diseases in Germany, (in million), 2015-2019
  • Figure 76: Estimated people with diabetes in Germany (in millions), 2021-2045
  • Figure 77: Prevalence of Multiple Sclerosis in Germany, (in 1000is), 2016-2019
  • Figure 78: Germany Current health expenditure per capita (current USD), 2015-2019
  • Figure 79: Germany Population aged 65 and above (% of total Population), 2016-20
  • Figure 80: Germany, Estimated percentage of prevalent Cancer cases, 2020
  • Figure 81: Germany Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 82: Germany Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 83: Germany Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 84: United Kingdom Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 85: Estimated people with diabetes in United Kingdom (in millions), 2021-2045
  • Figure 86: United Kingdom, Estimated percentage of prevalent Cancer cases, 2020
  • Figure 87: Prevalence of Multiple Sclerosis in United Kingdom, (in 1000is), 2015-2019
  • Figure 88: United Kingdom Current health expenditure per capita (current USD), 2015-2019
  • Figure 89: United Kingdom Population aged 65 and above (% of total Population), 2016-20
  • Figure 90: Prevalence of Cardiovascular Diseases in United Kingdom, (in million), 2015-2019
  • Figure 91: United Kingdom Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 92: United Kingdom Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 93: United Kingdom Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 94: France Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 95: Estimated people with diabetes in France (in millions), 2021-2045
  • Figure 96: France, Estimated percentage of prevalent Cancer cases, 2020
  • Figure 97: Prevalence of Multiple Sclerosis in France, (in 1000is), 2015-2019
  • Figure 98: France Current health expenditure per capita (current USD), 2015-2019
  • Figure 99: France Population aged 65 and above (% of total Population), 2016-20
  • Figure 100: Prevalence of Cardiovascular Diseases in France, (in million), 2015-2019
  • Figure 101: France Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 102: France Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 103: France Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 104: Italy Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 105: Estimated people with diabetes in Italy (in millions), 2021-2045
  • Figure 106: Italy, Estimated percentage of prevalent Cancer cases, 2020
  • Figure 107: Prevalence of Multiple Sclerosis in Italy, (in 1000is), 2015-2019
  • Figure 108: Italy Current health expenditure per capita (current USD), 2015-2019
  • Figure 109: Italy Population aged 65 and above (% of total Population), 2016-20
  • Figure 110: Prevalence of Cardiovascular Diseases in Italy, (in million), 2015-2019
  • Figure 111: Italy Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 112: Italy Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 113: Italy Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 114: Asia Pacific Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 115: Prevalence of Cardiovascular Diseases in Asia Pacific, (in million), 2015-2019
  • Figure 116: Cancer prevalence in Asia Pacific (in thousands), Year 2020
  • Figure 117: Asia Pacific Diabetes Prevalence, By Country, 2020 (% of Population Aged 20 to 79)
  • Figure 118: Asia Pacific Current health expenditure per capita (current USD), 2014-18
  • Figure 119: Asia Pacific, Current health expenditure per capita, by countries (current USD), 2019
  • Figure 120: Asia Pacific, Population ages 65 and above (% of total Population), 2016-20
  • Figure 121: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
  • Figure 122: Asia Pacific Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 123: Asia Pacific Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 124: Asia Pacific Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 125: Market Opportunity Chart of Asia Pacific Generic Injectables Market- By Country, By Value (Year-2026)
  • Figure 126: Asia Pacific Generic Injectables Market- By Country Market Share, 2021 & 2027
  • Figure 127: China Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 128: Estimated people with diabetes in China (in millions), 2021-2045
  • Figure 129: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
  • Figure 130: Estimated number of Cancer prevalent cases in China (all ages, in 1000is), Year 2020
  • Figure 131: China Current health expenditure per capita (current USD), 2015-2019
  • Figure 132: China Population aged 65 and above (% of total Population), 2016-20
  • Figure 133: China Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 134: China Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 135: China Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 136: Japan Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 137: Estimated people with diabetes in Japan (in millions), 2021-2045
  • Figure 138: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
  • Figure 139: Estimated number of Cancer prevalent cases in Japan (all ages, in 1000is), Year 2020
  • Figure 140: Japan Healthcare Expenditure Outlook (%)
  • Figure 141: Japan Population aged 65 and above (% of total Population), 2016-20
  • Figure 142: Japan Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 143: Japan Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 144: Japan Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 145: India Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 146: Estimated people with diabetes in India (in millions), 2021-2045
  • Figure 147: Estimated number of Cancer prevalent cases in India (all ages, in 1000is), Year 2020
  • Figure 148: Prevalence of Multiple Sclerosis in India, (in 1000is), 2016-2019
  • Figure 149: Estimated value of public health spending in India (from 2017-20, in billions USD)
  • Figure 150: India Population aged 65 and above (% of total Population), 2016-20
  • Figure 151: Prevalence of Cardiovascular Diseases in India, (in million), 2015-2019
  • Figure 152: India Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 153: India Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 154: India Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 155: Australia Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)
  • Figure 156: Estimated people with diabetes in Australia (in millions), 2021-2045
  • Figure 157: Estimated number of Cancer prevalent cases in Australia (all ages, in 1000is), Year 2020
  • Figure 158: Prevalence of Multiple Sclerosis in Australia, (in 1000is), 2016-2019
  • Figure 159: Australia Current health expenditure per capita (current USD), 2015-2019
  • Figure 160: Australia Population aged 65 and above (% of total Population), 2016-20
  • Figure 161: Prevalence of Cardiovascular Diseases in Australia, (in million), 2015-2019
  • Figure 162: Australia Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027
  • Figure 163: Australia Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027
  • Figure 164: Australia Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027
  • Figure 165: Market Attractiveness Chart of Global Generic Injectables Market- By Molecule Type (Year-2027)
  • Figure 166: Market Attractiveness Chart of Global Generic Injectables Market- By Therapeutic Area (Year-2027)
  • Figure 167: Market Attractiveness Chart of Global Generic Injectables Market- By Container (Year-2027)
  • Figure 168: Market Attractiveness Chart of Global Generic Injectables Market- By Region (Year-2027)
  • Figure 169: Global Generic Injectables company market share (%), 2021
  • Figure 170: Market share in generic injectables in US (by value), 2021
  • Figure 171: Market share in generic injectables in US (by volume), 2021
  • Figure 172: Pfizer Inc. Annual Sales Revenue, 2016-2020 (USD Million)
  • Figure 173: Pfizer Inc. Net Income, 2016-2020 (USD Million)
  • Figure 174: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2020
  • Figure 175: Novartis Annual Sales Revenue (USD Million), 2016-2020
  • Figure 176: Novartis Annual Net Income/Loss (USD Million), 2016-2020
  • Figure 177: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
  • Figure 178: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 179: Sanofi Sales Revenues, 2016-2020 (USD Million)
  • Figure 180: Sanofi Gross Profit, 2016-2020 (USD Million)
  • Figure 181: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 182: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 183: Baxter International Sales Revenues, 2016-2020 (USD Million)
  • Figure 184: Baxter International Net Income, 2016-2020 (USD Million)
  • Figure 185: Baxter International Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 186: Baxter International Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 187: Fresenius SE & Co KGaA Sales Revenues, 2016-2020 (USD Million)
  • Figure 188: Fresenius SE & Co KGaA Net Income, 2016-2020 (USD Million)
  • Figure 189: Fresenius SE & Co KGaA Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 190: Fresenius SE & Co KGaA Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 191: Amneal Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
  • Figure 192: Amneal Pharmaceuticals Net Income, 2016-2020 (USD Million)
  • Figure 193: Amneal Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 194: Amneal Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 195: Hikma Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
  • Figure 196: Hikma Pharmaceuticals Net Income, 20016-2020 (USD Million)
  • Figure 197: Hikma Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 198: Hikma Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 199: Gland Pharma Annual Sales Revenue (USD Million), 2017-2020
  • Figure 200: Gland Pharma Net Income (USD Million), 2017-2020
  • Figure 201: Gland Pharma Sales Revenue, By Business Segment (%), FY2020
  • Figure 202: Gland Pharma Sales Revenue, By Geographical Segment (%), FY2020
  • Figure 203: Teva Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)
  • Figure 204: Teva Pharmaceuticals Net Income, 2016-2020 (USD Million)
  • Figure 205: Teva Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 206: Teva Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020
  • Figure 207: Nichi-iko Pharmaceutical Sales Revenues, 2016-2020 (USD Million)
  • Figure 208: Nichi-iko Pharmaceutical Net Income, 2016-2020 (USD Million)
  • Figure 209: Nichi-iko Pharmaceutical Sales Revenue Split, By Business Segment (%), FY2020
  • Figure 210: Nichi-iko Pharmaceutical Sales Revenue Split, By Geography Segment (%), FY2020
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!